None listed
Conditions
Brief summary
The administration of intravenous fluid is a common therapy in acutely unwell patients. The study will provide preliminary data from a large interventional trial to inform clinicians looking after acutely unwell patients as to whether 0.9% saline or Plasma-Lyte 148 'Registered Trademark' is the preferred fluid for routine use in the ICU.
Interventions
0.9% saline for intravenous fluid therapy in intensive care. The rate, duration, and frequency of fluid administration will determined by the treated clinician. All fluid used for either fluid resuscitation or crystalloid rehydration will be 0.9% saline unless a specific indication exists for another fluid. Each of the four study ICUs will be randomly assigned, in alternating seven week blocks, to use blinded 0.9% saline or Plasma-Lyte 148 as the default resuscitation fluid. There will be no
0.9% saline for intravenous fluid therapy in intensive care. The rate, duration, and frequency of fluid administration will determined by the treated clinician. All fluid used for either fluid resuscitation or crystalloid rehydration will be 0.9% saline unless a specific indication exists for another fluid. Each of the four study ICUs will be randomly assigned, in alternating seven week blocks, to use blinded 0.9% saline or Plasma-Lyte 148 as the default resuscitation fluid. There will be no wash-out period between treatments. Each patient will receive the treatment they were assigned at the time of their ICU admission for the entire duration of their ICU admision irrespective of whether a cross-over occurs while they are admitted.
Sponsors
Medical Research Institute of New Zealand
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No
Inclusion criteria
Patients admitted to the study ICU who require crystalloid fluid therapy
Exclusion criteria
1. patients currently receiving or expected to require renal replacement therapy within six hours of ICU admission 2. patients who are usually on dialysis for end stage renal failure 3. patients who are admitted to the ICU solely for consideration of organ donation or for palliative care 4. patients previously enrolled in the SPLIT study
Outcome results
None listed